Regulatory FDA delays verdict on AZ breast cancer drug PharmaphorumAfter an advisory committee setback, AstraZeneca has a chance to make the case for its oral SERD camizestrant for breast cancer.OncologyRead full story pharminent May 27, 2026 (Last updated: May 27, 2026) Pharmaphorum After an advisory committee setback, AstraZeneca has a chance to make the case for its oral SERD camizestrant for breast cancer. Oncology Read full story Post navigation Previous: Early data for heart drug affirm Lilly’s billion-dollar bet on VerveNext: Kardigan targets IPO to support cardiology pipeline progression Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
